{"DataElement":{"publicId":"4538452","version":"1","preferredName":"Specimen Leukemia Immunophenotype Type","preferredDefinition":"the type of leukemia cell or tissue from a biological sample collected for the purpose of performing for phenotype (expressed antigen) testing.","longName":"ImmunoLeukTp","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"4541125","version":"1","preferredName":"Specimen Leukemia Immunophenotype","preferredDefinition":"information related to the leukemia cell or tissue from a biological sample collected for the purpose of performing for phenotype (expressed antigen) testing.","longName":"SpcLeukImmuntp","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177026","version":"1","preferredName":"Specimen","preferredDefinition":"Specimen; a bit of tissue or blood or urine that is taken or used for research purposes.","longName":"Specimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AE7-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4541123","version":"1","preferredName":"Leukemia Immunophenotype","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.:The characterization of a set of cells according to the antigens expressed.","longName":"C3161:C20072","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunophenotype","conceptCode":"C20072","definition":"The characterization of a set of cells according to the antigens expressed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A2787C-3D12-D84A-E050-BB89AD4368AB","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"ONEDATA","dateModified":"2014-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A2787C-3D23-D84A-E050-BB89AD4368AB","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4538431","version":"1","preferredName":"Immunophenotype Cell Specimen Type","preferredDefinition":"the type of cell or tissue from a biological sample collected for the purpose of performing for phenotype (expressed antigen) testing.","longName":"ImmuClSpcTp","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"B-precursor","valueDescription":"B-precursor","ValueMeaning":{"publicId":"4539899","version":"1","preferredName":"B-precursor","longName":"4539899","preferredDefinition":"B-precursor","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A1D7B2-8D68-383E-E050-BB89AD433BD5","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A1D7B2-8D81-383E-E050-BB89AD433BD5","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"ONEDATA","dateModified":"2014-10-17","deletedIndicator":"No"},{"value":"No leukemia population identified","valueDescription":"No leukemia population identified","ValueMeaning":{"publicId":"4539900","version":"1","preferredName":"No leukemia population identified","longName":"4539900","preferredDefinition":"No leukemia population identified","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A1D7B2-8D8B-383E-E050-BB89AD433BD5","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A1D7B2-8DA4-383E-E050-BB89AD433BD5","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"ONEDATA","dateModified":"2014-10-17","deletedIndicator":"No"},{"value":"Acute Leukemia of Ambiguous Lineage","valueDescription":"Acute Leukemia of Ambiguous Lineage","ValueMeaning":{"publicId":"2835647","version":"1","preferredName":"Acute Leukemia of Ambiguous Lineage","longName":"2835647","preferredDefinition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells.  The prognosis is usually unfavorable.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia of Ambiguous Lineage","conceptCode":"C7464","definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-667C-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":"2023.3.13 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A1D7B2-8DAE-383E-E050-BB89AD433BD5","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"ONEDATA","dateModified":"2014-10-17","deletedIndicator":"No"},{"value":"Not B precursor ALL, diagnosis not further specified","valueDescription":"Not B precursor ALL, diagnosis not further specified","ValueMeaning":{"publicId":"4539844","version":"1","preferredName":"Not B precursor ALL, diagnosis not further specified","longName":"4539844","preferredDefinition":"Not B precursor ALL, diagnosis not further specified","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A1992B-836B-76CD-E050-BB89AD4365DA","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A1992B-8384-76CD-E050-BB89AD4365DA","beginDate":"2014-10-16","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-17","modifiedBy":"ONEDATA","dateModified":"2014-10-17","deletedIndicator":"No"},{"value":"Not evaluated","valueDescription":"Not evaluated","ValueMeaning":{"publicId":"2769814","version":"1","preferredName":"Not evaluated","longName":"2769814","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5359582D-379B-2F8C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"058F579C-8D3A-3DA1-E050-BB89AD436D0B","beginDate":"2014-10-16","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-16","modifiedBy":"ONEDATA","dateModified":"2014-10-16","deletedIndicator":"No"},{"value":"B-Cell (Burkitt s)","valueDescription":"B-Lymphocyte","ValueMeaning":{"publicId":"2581328","version":"1","preferredName":"B-Lymphocyte","longName":"2581328","preferredDefinition":"Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0ABD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-24","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E614D8C-79E2-67FC-E053-F662850A1F1D","beginDate":"2018-06-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-06-11","modifiedBy":"ONEDATA","dateModified":"2018-06-11","deletedIndicator":"No"},{"value":"T-Cell","valueDescription":"T-Lymphocyte","ValueMeaning":{"publicId":"2581332","version":"1","preferredName":"T-Lymphocyte","longName":"2581332","preferredDefinition":"One type of white blood cell that attacks virus-infected cells, foreign cells, and cancer cells.  T cells also produce a number of substances that regulate the immune response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0AC1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-24","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6E614D8C-79F7-67FC-E053-F662850A1F1D","beginDate":"2018-06-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-06-11","modifiedBy":"ONEDATA","dateModified":"2018-06-11","deletedIndicator":"No"},{"value":"ALL","valueDescription":null,"ValueMeaning":{"publicId":"4263934","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"4263934","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood.  It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-343E-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6CC6148-D90A-691B-E053-731AD00A238A","beginDate":"2023-03-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-13","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","deletedIndicator":"No"},{"value":"AML","valueDescription":null,"ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6CC6148-D90B-691B-E053-731AD00A238A","beginDate":"2023-03-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-13","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","deletedIndicator":"No"},{"value":"MPAL","valueDescription":null,"ValueMeaning":{"publicId":"7000422","version":"1","preferredName":"Mixed Phenotype Acute Leukemia","longName":"7000422","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950E57BC-8DF0-20B0-E053-F662850A4478","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6CC6148-D90C-691B-E053-731AD00A238A","beginDate":"2023-03-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-13","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6CC6148-D90D-691B-E053-731AD00A238A","beginDate":"2023-03-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-13","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","deletedIndicator":"No"},{"value":"B-ALL","valueDescription":null,"ValueMeaning":{"publicId":"4263974","version":"1","preferredName":"B Acute Lymphoblastic Leukemia","longName":"4263974","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1156-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F93011CC-9B1A-44B8-E053-731AD00A6277","beginDate":"2023-04-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-12","modifiedBy":"GDEEN","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"T-ALL","valueDescription":null,"ValueMeaning":{"publicId":"4263973","version":"1","preferredName":"T Acute Lymphoblastic Leukemia","longName":"4263973","preferredDefinition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1133-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F93011CC-9B1B-44B8-E053-731AD00A6277","beginDate":"2023-04-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-12","modifiedBy":"GDEEN","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"AUL","valueDescription":null,"ValueMeaning":{"publicId":"3322385","version":"1","preferredName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","longName":"3322385v1.00","preferredDefinition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia with BCR-ABL1 Fusion","conceptCode":"C82192","definition":"A rare mixed phenotype acute leukemia in which the blasts carry the chromosomal translocation t(9;22)(q34.1;q11.2) that results in BCR-ABL1 gene fusion. The prognosis is usually unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB97-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC752172-B62C-633A-E053-731AD00A0183","beginDate":"2023-05-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-24","modifiedBy":"KUMMEROA","dateModified":"2023-05-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058F579C-8CB3-3DA1-E050-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-05-24","changeDescription":null,"administrativeNotes":"2023.5.24 PV added per ticket request CADSR0002456. ak 2023.3.13 PVs added per ticket request CADSR0002119. ak 2023.3.1 OK to change ownership per GD to COG due to origin. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Immunophenotype:","type":"Preferred Question Text","description":"Immunophenotype:","url":null,"context":"CTEP"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"058F487B-4AA6-00E0-E050-BB89AD43180E","latestVersionIndicator":"Yes","beginDate":"2014-10-16","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-16","modifiedBy":"WONGW","dateModified":"2014-10-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}